Adolescent substance-use screening, brief intervention and harm reduction — branching viva

Stem

The examiner will test whether you can run SBIRT under pressure and defend harm reduction as a clinical philosophy rather than an excuse. [3] [1]

Branch 1 — Philosophy and SBIRT

Examiner: What is SBIRT, and is harm reduction the same as enabling? [1] [3]

Strong answer: SBIRT — Screening, Brief Intervention, and Referral to Treatment — is the AAP-endorsed workflow in which every adolescent is screened for substance use, those with risk receive a brief intervention, and indicated cases are referred to treatment. Harm reduction is the pragmatic stance that lowers the adverse consequences of use even when the use continues. It is not enabling: a dead or HIV-positive adolescent cannot make any future change. Abstinence remains one possible goal, not the only acceptable outcome. [1] [3] [6]

Examiner: Why does abstinence-only fail here? [6]

Strong answer: The dual-systems model: reward matures before prefrontal control through mid-adolescence, so under peer and emotional load an adolescent may intend not to use and still use. Demanding willpower alone disengages the highest-risk youth. [6]

Branch 2 — Universal screening

Examiner: How do you screen, and how does the response tier? [1]

Strong answer: Every adolescent gets a validated universal screen. S2BI asks past-year use frequency per substance and tiers: no use (re-screen), 1–2 times (brief advice), monthly or more (full assessment + brief intervention + referral). CRAFFT (Car, Relax, Alone, Forget, Friends, Trouble) is the deeper/back-up screen; two or more "yes" items signal a high likelihood of a problem. A positive screen is a trigger for same-visit clinical thinking, never a diagnosis. [1] [2]

Branch 3 — Positive cannabis and vaping lead

Examiner: A 15-year-old vapes daily and uses cannabis monthly. Function intact. What next? [1]

Strong answer: Move from screen to structured assessment: pattern, route, age of initiation, dependence features, co-occurring mood or psychotic features, educational decline, and fentanyl-exposure risk if any pill/powder. Then deliver a brief intervention with motivational interviewing (OARS) to evoke their own reasons for change. For vaping, offer a cut-down plan, step-down nicotine, behavioural support, and consider varenicline where locally approved and age-appropriate — a 2025 RCT demonstrated efficacy for youth nicotine vaping cessation. For cannabis, delay initiation, reduce frequency and potency, treat co-occurring mood, and link to behavioural therapy if use-disorder criteria are met. [1] [7] [5]

Branch 4 — Fentanyl-era opioid disclosure

Examiner: A 17-year-old took pills "to relax"; fentanyl exposure is possible. What is the bundle? [4]

Strong answer: Take-home naloxone plus overdose education for the young person and, with consent, family or peers; safer-use messaging (no mixing, start low, never alone); opioid-use-disorder assessment and MOUD linkage; needle–syringe access and blood-borne-virus testing if injecting. Bundle sexual-health and mental-health harm reduction. Non-judgemental, low-threshold, follow locally approved naloxone product and protocol. [4] [3]

Branch 5 — Confidentiality and systems

Examiner: The parent portal will show the naloxone plan. [1]

Strong answer: Substance-use care can stay confidential unless serious risk overrides. Use local sensitive-note workflows, minimise unnecessary disclosure, and check portal defaults so harm-reduction care is not leaked. Explain the limits of confidentiality to the young person up front and document the reasoning. [1] [6]

Examiner extras

• Harm reduction keeps young people alive and engaged; engagement is itself an outcome. [3] [6]
• Name the method: motivational interviewing evokes change rather than imposing it; meta-analytic support. [5]
• State that local statute governs consent ages, reporting triggers and naloxone access — do not invent universal cut-offs. [1]
• Varenicline for youth vaping cessation has 2025 RCT support; follow locally approved prescribing guidance and age thresholds. [7]